A Cure in Sight, in collaboration with the Ocular Melanoma Foundation, is joined by TriSalus Life Sciences to bring you a presentation on Barriers to Immunotherapy: Success for Uveal Melanoma Liver Metastases.

In this presentation, we will be hearing from three of the experts involved in the PERIO-01 Clinical Trial.

The Pressure-Enabled Regional Immuno-Oncology (PERIO-01) clinical trial is studying a new investigational drug, SD-101, delivered intravascularly by the TriNav® Infusion System using the Pressure-Enabled Drug Delivery™ (PEDD™) method of administration. The study is evaluating if this platform approach can improve the performance of systemic checkpoint inhibitors in treating patients with uveal melanoma liver metastases by overcoming two major challenges of treatment: immune response suppression and ineffective drug delivery.

First up, you’ll hear from Dr. Richard D. Carvajal, MD, Associate Professor of Medicine, Director, Experimental Therapeutics, Director, Melanoma Service, Columbia University Irving Medical Center; Investigator, PERIO-01 Clinical Trial. Dr. Carvajal will discuss Successes, Challenges and Emerging Strategies in the Treatment of Metastatic Uveal Melanoma.

Following his presentation, Dr. Steven C. Katz, MD, FACS, Chief Medical Officer, TriSalus Life Sciences will discuss Barriers to Immunotherapy Success in Uveal Melanoma Liver Metastases.
To conclude you’ll hear from Dr. Joshua L. Weintraub, MD, Executive Vice Chairman, Department of Radiology, Chief, Division of Vascular and Interventional Radiology, Columbia University Irving Medical Center about the Pressure-Enabled Regional Immuno-Oncology (or PERIO-01) Clinical Trial for adults with uveal melanoma liver metastases.

After their presentation, Ashley Moody from TriSalus Life Sciences joins in to aid in the Q and A. Ashley is a Nurse and a Clinical Research and Immunotherapy Project Manager. She will answer logistical questions surrounding trial involvement (eligibility, trial flow, treatment logistics, travel reimbursement, if applicable, etc.) following the presentation.

Information on the PERIO-O1 Clinical Trial can be found at [ Ссылка ]

свернуть